论文部分内容阅读
在肿瘤疫苗治疗前后 ,如何准确的定量、定性判定肿瘤抗原特异性T细胞反应 ,评价疗效 ,是影响抗肿瘤疫苗发展的关键。ELISPOT法是近年来逐渐建立起来的一种通过检测细胞因子评价T淋巴细胞功能和特异性的新方法。它能够对T淋巴细胞直接进行检测 ,不需要体外扩增 ,特异性、敏感性都有所提高。经过可行性分析和多中心对比研究 ,该技术不仅可用于监测肿瘤疫苗的疗效 ,也能用来鉴定肿瘤抗原表位。很有可能在完成的与其他方法的比较后ELISPOT将会成为定量分析肿瘤或病毒特异性的T细胞反应的首选。
Before and after the treatment of tumor vaccine, how to quantitatively and qualitatively determine tumor antigen-specific T cell response and evaluate the efficacy is the key to the development of anti-tumor vaccine. ELISPOT method is gradually established in recent years through the detection of cytokines T lymphocytes function and specificity of the new method. It can directly test T lymphocytes, does not require in vitro amplification, specificity, sensitivity have increased. After the feasibility analysis and multicenter comparative study, this technique can not only be used to monitor the efficacy of tumor vaccines, but also can be used to identify tumor epitopes. It is likely that ELISPOT will be the first choice for quantitative analysis of tumor-specific or virus-specific T-cell responses after completion of comparison with other methods.